Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.
The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.
Here is some other vaccine news of note for the week.
CureVac is working on a printer to quickly create mRNA vaccine candidates against known pathogens and unknown diseases.
The power struggle at Sinovac has taken another unusual turn with the company's move to implement a "poison pill" defense.
Themis' win comes after the FDA granted the same designation to chikungunya candidates from PaxVax and Valneva.
The company aims to enter the clinic with a pan-flavivirus vaccine against Zika, dengue and yellow fever in 2019.
Sanofi has faced more than a year of controversy for its dengue vaccine, and now Philippine officials have revoked Dengvaxia's regulatory approval.
After the buy, Bharat Biotech will be able to make 25 million doses of rabies vaccine each year, its chairman said.